Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
29. Januar 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
23. Januar 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
– Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market – LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive...
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
18. Dezember 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
29. November 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for...
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
14. November 2023 16:15 ET
|
Unicycive Therapeutics, Inc.
Reached Alignment with the FDA on the Data Package Requirements to File NDA for oxylanthanum carbonate (OLC) OLC Pivotal Clinical Trial Expected to Initiate Before Year End LOS ALTOS, Calif., Nov. ...
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
23. Oktober 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
- Pivotal clinical trial expected to initiate before year end - LOS ALTOS, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology...
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
06. September 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
29. August 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
14. August 2023 17:36 ET
|
Unicycive Therapeutics, Inc.
Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA...
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
20. Juli 2023 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...